Tateishi developed a prognostic model for patients with hepatocellular carcinoma. This can help identify patients who may benefit from more aggressive management. The authors are from the University of Tokyo.
Parameters:
(1) number of tumors
(2) size of the tumor in cm
(3) serum albumin in g/dL
(4) serum total bilirubin in mg/dL
|
Parameter |
Finding |
Points |
|
number of tumor nodules |
1 to 3 |
0 |
|
|
4 or more |
2 |
|
size of the tumor (diameter in cm) |
< 2 cm |
0 |
|
|
2 to 5 cm |
1 |
|
|
> 5 cm |
2 |
|
serum albumin |
> 3.5 g/dL |
0 |
|
|
2.8 to 3.5 g/dL |
1 |
|
|
< 2.8 g/dL |
2 |
|
serum total bilirubin |
< 1 mg/dL |
0 |
|
|
1 to 2 mg/dL |
1 |
|
|
> 2 mg/dL |
2 |
where:
• The definition for tumor size was not given. I assume that it is the sum of the tumor nodule diameters if there is more than 1 nodule.
total score =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 8
• The higher the score the more severe the disease.
|
Total Score |
5 Year Survival Rate |
|
0 |
79% |
|
1 |
62% |
|
2 |
40% |
|
3 |
28% |
|
4 to 6 |
14% |
|
7 or 8 |
NA |
Specialty: Hematology Oncology, Surgery, general, Gastroenterology
ICD-10: ,
